- Home
- MIRA vs CVKD Comparison
MIRA vs CVKD Comparison
Compare MIRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CVKD
- Stock Information
- Founded
- MIRA 2020
- CVKD 2022
- Country
- MIRA United States
- CVKD United States
- Employees
- MIRA N/A
- CVKD N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- MIRA Health Care
- CVKD Health Care
- Exchange
- MIRA Nasdaq
- CVKD Nasdaq
- Market Cap
- MIRA 27.7M
- CVKD 27.0M
- IPO Year
- MIRA 2023
- CVKD 2023
- Fundamental
- Price
- MIRA $1.66
- CVKD $12.88
- Analyst Decision
- MIRA
- CVKD Strong Buy
- Analyst Count
- MIRA 0
- CVKD 1
- Target Price
- MIRA N/A
- CVKD $32.00
- AVG Volume (30 Days)
- MIRA 8.8M
- CVKD 25.0K
- Earning Date
- MIRA 11-14-2025
- CVKD 11-07-2025
- Dividend Yield
- MIRA N/A
- CVKD N/A
- EPS Growth
- MIRA N/A
- CVKD N/A
- EPS
- MIRA N/A
- CVKD N/A
- Revenue
- MIRA N/A
- CVKD N/A
- Revenue This Year
- MIRA N/A
- CVKD N/A
- Revenue Next Year
- MIRA N/A
- CVKD N/A
- P/E Ratio
- MIRA N/A
- CVKD N/A
- Revenue Growth
- MIRA N/A
- CVKD N/A
- 52 Week Low
- MIRA $0.73
- CVKD $8.74
- 52 Week High
- MIRA $2.56
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- MIRA 60.49
- CVKD 45.05
- Support Level
- MIRA $1.36
- CVKD $12.11
- Resistance Level
- MIRA $1.80
- CVKD $14.21
- Average True Range (ATR)
- MIRA 0.17
- CVKD 0.72
- MACD
- MIRA 0.03
- CVKD -0.11
- Stochastic Oscillator
- MIRA 34.17
- CVKD 32.22
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.